BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14

• Press Releases

  Bruker Reports Second Quarter 2026 Financial Results

  August 4, 2026

   · 

  20 min read
• Press Releases

  Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

  August 4, 2026

   · 

  2 min read
• Press Releases

  Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases

  August 4, 2026

   · 

  4 min read
• Press Releases

  CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

  August 4, 2026

   · 

  5 min read
• Press Releases

  Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  August 4, 2026

   · 

  14 min read
• Press Releases

  Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

  August 4, 2026

   · 

  16 min read
• Press Releases

  Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

  August 4, 2026

   · 

  6 min read
• Press Releases

  Satellite Bio Announces FDA Clearance of IND Application for SB-101 for the Treatment of Urea Cycle Disorders (UCDs) Marking its Transition to a Clinical-Stage Biotechnology Company

  August 4, 2026

   · 

  3 min read
• Press Releases

  ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

  August 4, 2026

   · 

  18 min read
• 

  Earnings

  Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure

  The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major products like the blood thinner Eliquis.

  August 4, 2026

   · 

  3 min read

   · 

  Annalee Armstrong